3SOF

 "CEO Cast letter - small print in readable size. Wow"

       


I guess if you disclose it, it is legal to pump and dump.  Never knew much about it. What a business.

This publication accepts compensation from companies that it features. This newsletter should not be regarded as an independent publication. Our editors may, from time to time, acquire positions in the companies that they cover. This could represent a conflict of interest. The CEOcast newsletter shall be under no obligation to inform readers about its trading activities. CEOcast's editors reserve the right to buy or sell shares in these companies at any time. The following companies, featured in this newsletter, have compensated CEOcast: Applied Digital, twelve thousand five hundred dollars per month, a21, ten thousand dollars per month and one hundred fifty thousand shares of stock for a six-month agreement, Advance Nanotech, ten thousand dollars per month and thirty thousand shares of stock for a one-year agreement, Black Dragon Resources, two hundred fifty thousand shares of stock from Joe Lanza, a third-party shareholder, Bio Bridge, five thousand dollars per month and one hundred thousand shares of stock for a six-month program. Clearant, ten thousand dollars per month and fifty thousand shares of stock for a one-year program, Citadel Security Software, seven thousand five hundred dollars per month and one hundred ten thousand shares of stock for a six-month program; CEOcast received fifty-three thousand shares of stock from previous agreements; an editor of CEOcast has purchase three hundred thousand shares of stock, China Energy Savings, seven thousand five hundred dollars and fifty thousand shares of stock for a one-year program, Compuprint, five thousand dollars per month and five hundred thousand shares of stock for a one-year program, Circle Group Holdings, six thousand dollars per month and sixty thousand shares for a five-month program; CEOcast received ninety thousand shares from previous programs, Emisphere Technologies, seventeen thousand five hundred dollars per month, Forbes Medi-Tech, ten thousand dollars per month, Generex Biotechnology, five thousand dollars per month and two hundred twenty five thousand shares of stock for a one-year program; CEOcast received five hundred twenty thousand shares from previous agreements, GreenShift Corporation, seven thousand five hundred dollars per month and eight hundred thousand shares of stock for a one-year program; CEOcast received five hundred thousand shares from previous agreement, Humware Media, five thousand dollars per month and one million four hundred thousand shares of stock, Home Solutions, seven thousand five hundred dollars per month and fifty thousand shares of stock, Hythiam, ten thousand dollars per month and twenty-five thousand shares of stock for a one-year program; CEOcast received seventeen thousand shares from a previous agreement; an editor/relatives of CEOcast employees have also purchased seven hundred eighty shares of stock, Itronics, six thousand dollars per month and two million warrants with an exercise price of sixteen cents, Novelos Therapeutics, ten thousand dollars Points International, ten thousand dollars per month, Patch International, seventy five hundred dollars per month and sixty thousand shares of stock, Protocall Technologies, seven thousand five hundred dollars per month and three hundred thousand shares of stock for a six-month program, Petrol Oil & Gas, seven thousand five hundred dollars per month and sixty thousand shares of stock for a one-year program; CEOcast received four hundred eighty thousand dollars and one hundred fifty thousand shares of stock for other services and under previous agreements, Rentech, seventeen thousand five hundred dollars per month for a six-month program, Sweet Success, five thousand dollars per month and three hundred thousand shares of stock, USA Technologies, ten thousand dollars per month, mPhase technologies, six thousand dollars per month and 300,000 shares of stock, Ziopharm, ten thousand dollars per month and twenty-five thousand shares of stock for a six-month program, Tarrant Apparel, seven thousand five hundred dollars per month and sixty thousand shares of stock for a one-year agreement, Enzo Biochem, seventeen thousand dollars per month, Linux Gold Corp., seven thousand five hundred dollars per month and three hundred fifty thousand shares of stock for a six-month program, Soyo Group, five thousand dollars per month and forty thousand shares of stock per month, Stinger Systems, seven thousand five hundred dollars per month and seventy-five thousand shares of stock for a one-year program.

Retracement Charts...I will get in this time around 

Upsloping trendline and 61.8% FIB projects around 2.50-2.60

Ditto with calven! I'm patiently waiting for the $2's...

http://dinvestor.com/2006/03/27/watchlist-for-week-of-327/

I still like a "tag" of the upsloping (blue) support line as an entry - that way I can justify taking the trade and not second guess myself with FIBs and all the other stuff....being a trendline trader, trendlines and volume are all i trust.

That soft area is similiar to a "gap" since very little volume occured there - relative to recent volume. I see that "soft area" getting a possible fill. This sets up perfect for a 2.60 entry.

Tenative Trading Plan: 
- 2 series of buys
- 1000 shares each
1st Buy: on a gap fill 2.60 also upsloping trendline support
2nd Buy: at 2.45 fib 61.8% projected support  (average down if necessary)
Stop Limit: 2.29 - A break of all technical support levels

cal 

HOLY COW - checked out your blog! We are virtually identical TA traders (trendlines, volume, and  PBV bars!) Amazing!!!  (APPLAUD!!!)

Just curious - how do the numbers in my trading plan agree with yours as far as the soft area and support levels both upsloping and horizontal???

We are definately on the same page here! - my new friend at 3sof... 

cal 

Insider update:
InsiderCow.com: A director of GNBT purchased 26,000 shares
Wednesday, March 29, 2006 02:50 ET

Mar 29, 2006 (M2 PRESSWIRE via COMTEX) -- Reported by InsiderCow.com at 10:21 AM EST, March 28, 2006: A director of Generex Biotechnology Corporation (GNBT) purchased 26,000 shares of GNBT from the open market. GNBT rose 6.76% since the InsiderCow.com report.

Trade amount: 26,000 shares
Trade type: Open Market Buy
Trade price range: $3.22
Transaction details at http://www.insidercow.com/history/company.jsp?company=GNBT Get real-time alerts on any insider trading information from www.insidercow.com, one step before everybody else.

&

Generex Slaps Back At Negative Internet Article, Completes New Insulin Loading Operation
Monday , March 27, 2006 23:45 ET

Mar 28, 2006 (financialwire.net via COMTEX) -- March 28, 2006 (FinancialWire) Generex Biotechnology (NASDAQ: GNBT) struck back at a negative Smart Money article with cries of inaccuracies and news of the completion of a turnkey operation for its oral insulin spray product in Quito, Ecuador.

The Smart Money article was taking aim at companies such as Novavax (NASDAQ: NVAX), BioCryst Pharmaceuticals (NASDAQ: BCRX), AVI Biopharma (NASDAQ: AVII), and Generex that are working on avian flu treatments, though none has a drug ready for consideration by the Food and Drug Administration.

The article referred to the company's "financial struggles." As indicated in the company's Form 10-Q Quarterly Report for the fiscal quarter ended January 31, 2006, Generex had cash and short-term investments in excess of $21 million as of January 31, 2006. As at the close of business on March 24, 2006, the company had cash and short-term investments in excess of $41 million, the strongest financial condition in the company's history.

The article states that "for the past year, Generex hasn't been able to pay off its debt." That statement is false, Generex said in its news release.

The article states that Generex failed to repay two promissory notes and that "[a]s a result the noteholders [sic] were allowed to convert the debt" into shares of common stock. That statement is false, Generex holds, explaining that the conversion entitlements were included in the promissory notes from the outset. The promissory notes were not repaid in cash on the maturity dates in the context of then on-going negotiations in respect of related transactions.

The author states that "Generex also agreed to such terms with other lenders," which is another false statement, Generex said.

Referring to what Generex calls "derisive reference to the company's losses," they say Generex is a development stage biotechnology corporation; accordingly, its function has been to spend money on research and development activities which expenditures are recorded as losses. He fails to mention that all of the other small biotechnology companies in the article incurred substantial losses for similar reasons. The author is correct, however, when he makes reference to the company's expectation of receiving revenue from the sale of Generex Oral-lyn(TM), the company's proprietary oral insulin spray product, by August 2006.

Generex also denies the author's statement that Generex is "a stock that faces the threat of delisting," with the claim that on November 15, 2005, the company announced that it had received written confirmation from the Nasdaq Stock Market that the company had achieved compliance with the continued listing requirements in accordance with Nasdaq Marketplace Rule 4310(c)(4). At the present time, Generex very comfortably meets all of the Nasdaq Stock Market quantitative continued listing requirements.

The article is correct when it states that the Antigen Express avian flu vaccine is in pre-clinical development (following a pre-IND meeting with the FDA on February 10, 2006) and that the Antigen Express breast cancer vaccine is in Phase 1 human clinical trials (at Walter Reed Army Medical Center).

"We do not seek to discourage critical review; however, we consider that such review should be based on accurate facts," stated Anna Gluskin, Generex's CEO. "The company made its executives available for the author to speak with. Unfortunately, whatever his underlying motives were, he chose to misstate and distort the facts thereby portraying the company in an unjustifiably negative manner."

Generex's stock was one of the day's 25 most active Nasdaq stocks, down 20.43% on volume of 35,838,571, over six times its average 5,725,380.

Concerning its new operation in Ecuador, Generex said a delivery and installation of a turnkey Generex Oral-lyn filling operation at the facilities of PharmaBrand, S.A. (www.pharmabrand.com.ec) in Quito, Ecuador, were completed. PharmaBrand is the Generex's joint venture partner for the commercialization of Generex Oral-lyn in Latin America. Generex Oral-lyn is designed to replace prandial subcutaneous injections of insulin by delivering insulin into the human body via a spray applied to the buccal mucosa using the company's proprietary RapidMist device.

A regulatory compliance and quality control team from Generex will attend at the PharmaBrand facilities early next month to assist in the training of PharmaBrand personnel in respect of the operation of the filling equipment. The company anticipates that the first commercial production run of 50,000 canisters of Generex Oral-lyn will be completed in April 2006. Prior to the commencement of that production run, PharmaBrand will have completed the training of its sales force in respect of the new diabetes treatment paradigm offered by Generex Oral-lyn's safe, simple, fast, effective, familiar, and pain-free alternative to prandial insulin injections for patients with either Type-1 or Type-2 diabetes.

The Generex team will also undertake an evaluation of the PharmaBrand manufacturing facilities with a view to assessing the prospect of utilizing those facilities for the production of proteins and peptides to support ongoing research and development in respect of the Antigen Express immunotherapeutic vaccines program.

Generex Biotech Corp. had enrolled in Investrend Research's unique and pioneering professional analyst program, which facilitates independent analysts to provide financial coverage for shareholders and investors in companies that otherwise would have little or no analyst following. Enrollment in standards-based research is an important measure of a company's commitment to transparency and Good Governance.

In a Focus Report initiated by Investrend Research analyst Shailesh Dhuri, the analyst stated on June 6, 2005, that the company "is working towards creating a potentially winning technology, with strong feature improvements over current options in the market."

GNBT: Shares Experiencing Short Squeeze
Wednesday, March 29, 2006 10:16 ET

Generex Biotechnology Corporation (GNBT) shares, up 4.75%, are experiencing a short squeeze. Last Friday, shares reached the $5 level before bears latched on and overwhelmed buyers.

The company has benefited from the birdflu coverage as well as their delivery method for a diabetes drug.

Thanks for your comments on 3SOF and my blog Calven!

My GNBT outlook is in-sync with yours: A good entry point with strong support is around $2.5-2.6 which coincides with the high volume by price bars.

I'm patientily waiting for the chance to get on the GNBT boat~ 

GNBT now @ $2.78... I was planning on re-entering when it hits the $2.60's.  Any opinions considering the rather volatile performance as of late. 

Also: I've only been trading for about 4 months and have checked out many forums and message boards but this one by far has the most proffesional and informative members. What I have learned about charts and trends is priceless and I hope to positively contribute as well in the future.

2.78 $ now....

Hi Calven and la-onda,

I will give you my input

First of all, I truly believe that GNBT will hit new highs this year, I may be wrong, but I think the Bird Flu hype is not over yet.

I was monitoring GNBT since the first big red candle in order to plan an entry... My first option was the first support (not solid enough), now it's broken, and I'm pointing to $2.15/$2.25 level to stop this blood shed.

Another good way to look at this, is by comparing GNBT now with NVAX in November 2005, but taking in consideration the flu hype is now on a different stage (that would speed up the following development).

In attach two charts: GNBT and NVAX (highlighting the November sell off).

Best regards and keep up your excellent work on our boards (both of you) !!! 

ps: I've merged this two GNBT topics

regards,

I have started to accumulate     

I have started too in the low $2.40's...

Good luck! 

Quote from: Ramsburg on April 03, 2006, 12:59:54 PM
Hi Calven and la-onda,

I will give you my input

First of all, I truly believe that GNBT will hit new highs this year, I may be wrong, but I think the Bird Flu hype is not over yet.

I was monitoring GNBT since the first big red candle in order to plan an entry... My first option was the first support (not solid enough), now it's broken, and I'm pointing to $2.15/$2.25 level to stop this blood shed.

Another good way to look at this, is by comparing GNBT now with NVAX in November 2005, but taking in consideration the flu hype is now on a different stage (that would speed up the following development).

In attach two charts: GNBT and NVAX (highlighting the November sell off).

Best regards and keep up your excellent work on our boards (both of you) !!! 

Thanks for your work also and your take on GNBT! I agree with everything you say and appreciate your post!


Now for my entry - With low comissions (4.99 for me) these days I believe in buying extremely speculative plays in a series (at least 2 or more buys) especially when trying to "catch the falling knife"  It can be extremely difficult to buy into these stocks near the bottom since they move so fast ,hence the reason for the series of buys 2-3. I usually take the first of my 2-3 buys at the upsloping trendline, then at a 61.8% FIB retracement level. The first of these two entry points was hit today. The next will likely be tested tomorrow... If we see 2.20's tomorrow I will definately be buying...

ESM CHART here - http://www.3stocksonfire.org/trading/index.php?topic=3555.new#new


GL all ! 

cal